<DOC>
	<DOC>NCT01765049</DOC>
	<brief_summary>Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness</brief_summary>
	<brief_title>Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor</brief_title>
	<detailed_description>Inclusion criteria ER positive breast cancer Postmenopause women Older than 60yr S/P bilateral salphingo-oophorectomy No menstruation history within 1yr and FSH&gt;30mIU/mL Ipsilateral invasive breast cancer Undergone curative resection No evidence of distant metastasis Capable of breast MRI</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>ER positive invasive breast cancer Postmenopause women age 60yrs or older s/p bilateral salphingooophorectomy No history of menstruation and FSH&gt;30mIU Planned for aromatase inhibitor Unilateral breast cancer Curative resection No evidence of distant metastasis Bilateral breast cancer Male breast cancer Acceptable for breast MRI Pregnancy or lactation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>breast density change</keyword>
	<keyword>endocrine therapy response</keyword>
	<keyword>aromatase inhibitor</keyword>
</DOC>